MacroGenics, Inc. M55.F Stock
MacroGenics, Inc. Price Chart
MacroGenics, Inc. M55.F Financial and Trading Overview
MacroGenics, Inc. stock price | 3.98 EUR |
Previous Close | 5.55 EUR |
Open | 5.45 EUR |
Bid | 5.45 EUR x 20000 |
Ask | 5.5 EUR x 20000 |
Day's Range | 5.45 - 5.45 EUR |
52 Week Range | 2.14 - 7.05 EUR |
Volume | 1K EUR |
Avg. Volume | 175 EUR |
Market Cap | 341.65M EUR |
Beta (5Y Monthly) | 1.994014 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.35 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 36.25 EUR |
M55.F Valuation Measures
Enterprise Value | 136.1M EUR |
Trailing P/E | N/A |
Forward P/E | -2.0185184 |
PEG Ratio (5 yr expected) | 0.03 |
Price/Sales (ttm) | 2.0664022 |
Price/Book (mrq) | 3.0843236 |
Enterprise Value/Revenue | 0.823 |
Enterprise Value/EBITDA | -1.675 |
Trading Information
MacroGenics, Inc. Stock Price History
Beta (5Y Monthly) | 1.994014 |
52-Week Change | 159.34% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.05 EUR |
52 Week Low | 2.14 EUR |
50-Day Moving Average | 5.83 EUR |
200-Day Moving Average | 5.3 EUR |
M55.F Share Statistics
Avg. Volume (3 month) | 175 EUR |
Avg. Daily Volume (10-Days) | 182 EUR |
Shares Outstanding | 61.84M |
Float | 54.16M |
Short Ratio | N/A |
% Held by Insiders | 2.68% |
% Held by Institutions | 93.18% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -55.23% |
Operating Margin (ttm) | -56.37% |
Gross Margin | -22.36% |
EBITDA Margin | -49.15% |
Management Effectiveness
Return on Assets (ttm) | -18.94% |
Return on Equity (ttm) | -63.53% |
Income Statement
Revenue (ttm) | 165.34M EUR |
Revenue Per Share (ttm) | 2.69 EUR |
Quarterly Revenue Growth (yoy) | 120.70% |
Gross Profit (ttm) | -62469000 EUR |
EBITDA | -81271000 EUR |
Net Income Avi to Common (ttm) | -91324000 EUR |
Diluted EPS (ttm) | -1.59 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 241.66M EUR |
Total Cash Per Share (mrq) | 3.91 EUR |
Total Debt (mrq) | 34.55M EUR |
Total Debt/Equity (mrq) | 31.62 EUR |
Current Ratio (mrq) | 6.335 |
Book Value Per Share (mrq) | 1.767 |
Cash Flow Statement
Operating Cash Flow (ttm) | -42096000 EUR |
Levered Free Cash Flow (ttm) | -63435752 EUR |
Profile of MacroGenics, Inc.
Country | Germany |
State | MD |
City | Rockville |
Address | 9704 Medical Center Drive |
ZIP | 20850 |
Phone | 301 251 5172 |
Website | https://www.macrogenics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 357 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Q&A For MacroGenics, Inc. Stock
What is a current M55.F stock price?
MacroGenics, Inc. M55.F stock price today per share is 3.98 EUR.
How to purchase MacroGenics, Inc. stock?
You can buy M55.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MacroGenics, Inc.?
The stock symbol or ticker of MacroGenics, Inc. is M55.F.
Which industry does the MacroGenics, Inc. company belong to?
The MacroGenics, Inc. industry is Biotechnology.
How many shares does MacroGenics, Inc. have in circulation?
The max supply of MacroGenics, Inc. shares is 62.63M.
What is MacroGenics, Inc. Price to Earnings Ratio (PE Ratio)?
MacroGenics, Inc. PE Ratio is now.
What was MacroGenics, Inc. earnings per share over the trailing 12 months (TTM)?
MacroGenics, Inc. EPS is -0.35 EUR over the trailing 12 months.
Which sector does the MacroGenics, Inc. company belong to?
The MacroGenics, Inc. sector is Healthcare.